Phase IIa ALS Clinical Trial with GM604, a Biotechnology Innovation, has been Approved
Offering imminent hope for those with ALS, Genervon Biopharmaceuticals, an innovative biotechnology company announced today that it has received FDA approval for its broadly inclusive ALS clinical trial. Learn more.